{"id":"clm_1526DF06387A","entity":"regeneron-pharmaceuticals","predicate":"total_assets","value":"15,757,500,000 United States dollar","value_json":{"fp":"Q1","fy":2020,"accn":"0001804220-20-000011","form":"10-Q","filed":"2020-05-05","period":"Q1 FY2020","concept":"us-gaap:Assets"},"valid_from":"2020-03-31","valid_to":"2020-06-30","published":"2020-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 15,757,500,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_1526DF06387A, https://asof.is/claim/clm_1526DF06387A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422020000011/0001804220-20-000011-index.htm.","url":"https://asof.is/claim/clm_1526DF06387A","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_644D82754410","supersedes":["clm_A8B1190C6433"],"first_seen_at":"2026-11-08T17:08:51.481862+00:00","updated_at":"2026-11-08T17:08:58.955536+00:00","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000180422020000011/0001804220-20-000011-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2020, filed 2020-05-05"},"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}